OLR1 and hematoma: Figure 5A showed that serum sLOX-1 levels significantly predicted poor prognosis at 3 months with AUC of 0.813 (95% CI, 0.731–0.879). In Figure 5B, the predictive ability of serum sLOX-1 levels was similar to GCS scores (AUC = 0.857; 95% CI, 0.781–0.915; p = 0.355) and hematoma volumes (AUC = 0.846; 95% CI, 0.768–0.906; p = 0.580).